NewLink Genetics (NLNK) Given a $26.00 Price Target by Cantor Fitzgerald Analysts
Cantor Fitzgerald set a $26.00 target price on NewLink Genetics (NASDAQ:NLNK) in a research report sent to investors on Friday. The brokerage currently has a buy rating on the biotechnology company’s stock.
Several other brokerages also recently weighed in on NLNK. Zacks Investment Research downgraded NewLink Genetics from a buy rating to a hold rating in a research report on Thursday, January 4th. Stifel Nicolaus increased their price target on NewLink Genetics from $25.00 to $29.00 and gave the stock a buy rating in a research report on Friday, November 3rd. Jefferies Group cut their price target on NewLink Genetics from $26.00 to $25.00 and set a buy rating on the stock in a research report on Friday, November 3rd. Finally, BidaskClub raised NewLink Genetics from a sell rating to a hold rating in a research report on Friday, January 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $21.57.
NewLink Genetics (NLNK) opened at $7.59 on Friday. NewLink Genetics has a 12-month low of $5.90 and a 12-month high of $25.17. The stock has a market capitalization of $281.42, a price-to-earnings ratio of -3.15 and a beta of 1.25.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.